🔗 Share this article

As the United States proceeds with historic changes to its vaccine recommendations, one figure has emerged in a surprising turn: Tracy Beth Høeg, a Danish American physician and epidemiologist who rose to prominence by questioning Covid vaccinations during the global health crisis and has focused upon possible deaths following COVID-19 vaccination in her short position at the Food and Drug Administration.

Planned Overhauls to Pediatric Vaccine Program

Health officials planned to announce major changes to the childhood vaccination calendar in December, synchronizing the US with Denmark’s vaccine program, sources say – a substantial departure that would put the US out of step with much of the global community with no evidence for improved outcomes. The planned update has been delayed until the next year.

Instead of the director of the vaccine center, Høeg is set to speak at the meeting. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the division this year.

A Shift at the Agency

This interim role might represent a tighter collaboration between the drug and biologics divisions as Høeg and Dr. Prasad solidify control at the FDA – and it signals a renewed priority upon dismantling long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for discontinuing some pediatric immunization guidelines in the US in order to be more similar to the Danish model, a country with universal health coverage and a number of inhabitants approximately the size of the state of Wisconsin.

So far public appearances, she has continued to focus on vaccination policy – usually the purview of Dr. Prasad, director of the FDA’s vaccine center – rather than drug regulation.

Questions Over Qualifications

Dr. Høeg has little discernible experience in medication creation, regulation or management, which has been typical for former leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the agency head and CBER since spring.

“It seems she lacks to have any of the qualifications” for leading the CDER, said Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in running a large organization. She is not an expert in pharmaceutical oversight.”

Previous directors of the center would “be deeply familiar with laws and regulations and the science of drug development”, commented Janet Woodcock. “Clearly, she lacks the sort of resume that prior appointees who headed the center have had.”

The drug center has an enormous portfolio at the FDA, she stated.

“Everybody just focuses on the innovative therapies, but the off-patent medication office authorizes numerous generic drugs. There is also a biologic copycat branch, OTC medication office and more, and each of these must be managed,” Dr. Woodcock noted. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Additionally, a significant administrative component to the role, which oversees in excess of 5,000 personnel. “It is a huge administrative position, if you perform it correctly,” she concluded.

Response and Contentious Programs

In response to concerns about Høeg’s qualifications and whether this appointment indicates greater collaboration among agency officials on vaccines, a press secretary said that the “questions are based on flawed premises”.

“Her experience is consistent with the duties of her job,” the official said, citing the months Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the commissioner’s new expedited review system, a contentious expedited drug-approval program that allegedly worried her predecessors. “How are these drugs being picked for this fast-track system? Who takes the choices?” Dr. Howard asked. “There is a lot of confidentiality occurring at the FDA right now.”

Overall, he said, “the FDA looks to be trending towards laxer regulations of most medications, with the exception of shots.”

Documented History on Vaccines

Concerning vaccines, Høeg has a more documented, if concerning, past, Howard have noted. She published a research paper using unverified volunteer-provided data to assess the frequency of heart inflammation following COVID-19 vaccination. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccinations are riskier than they are.

Among her “policy goals” for the incoming government included altering guidelines for novel immunizations and ending “unnecessary” vaccines, she remarked after the election on a podcast. At the FDA, Høeg has reportedly proposed excluding adolescent males from obtaining Covid vaccinations.

“She is an complete ideologue who begins with her conclusions and tailors the evidence to accommodate the science in a very disingenuous, fraudulent way,” Howard stated.

Taking Control and a “Revenge Tour”

Dr. Høeg joined other dissenters, {like|